Lou Gehrig's disease patient: Brainstorm Cell treatment helped me

Avichai Kremer is the first patient to be treated with Brainstorm Cell's drug, NurOwn, on the basis of a special approval.

A patient with amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) has testified to the effectiveness of the stem cell-based treatment for the disease being developed by Brainstorm Cell Therapeutics Ltd. (Bulletin Board:BCLI).

In a letter obtained by "Globes", Avichai Kremer stated, "I was diagnosed (with ALS) seven years ago at age 29. Today I am almost completely paralyzed and can’t walk, talk, or eat (I use a feeding tube). I am writing this letter using my head. ALS/MND has no effective treatment and diagnosis means a death sentence even today, a decade into the 21st century.

"Nevertheless, I was fortunate to be the first to get the stem cells treatment of Brainstorm Cell Therapeutics two and a half months ago (October 2010) at Hadassah hospital in Jerusalem, Israel. The procedure was simple and quick. Within 24 hours I was back home. Two and a half months later, I can testify that the Brainstorm treatment is completely safe and that my condition didn’t deteriorate in that time. In fact, not only did the disease seem to slow/stop in that time period, but preliminary follow-up tests done at Hadassah showed slight improvement in several physical functions such as breathing and speech."

Kremer is the first patient to be treated with Brainstorm Cell's drug, NurOwn, on the basis of a special approval. The treatment is not part of the clinical trials that are conducted to establish statistical analyses of a drug's efficacy and safety. The company is currently conducting a Phase I/II clinical trial of the drug.

Treatment with a drug without US Food and Drug Administration (FDA) or Ministry of Health approval of a single patient is an extraordinary procedure, given in incurable diseases. Such cases are usually handled at the medical center that is also conducting the clinical trial, and the results are not always sent to the company that is developing the drug.

Brainstorm Cell initiated the clinical trial of NurOwn last month, and is currently selecting patients for participation. If the treatment is successful, it could be a historic achievement, as there is no treatment for ALS, and sufferers die within 2-5 years. However, success in a single patient often cannot be replicated, and is statistically meaningless in a clinical trial and have no bearing on approval of the drug.

Nonetheless, Kremer's letter is the first indication of possible success of Brainstorm Cell's treatment - provided that the clinical trial achieves similar results. A successful treatment opens the $1 billion a year ALS market before the company.

Brainstorm Cell declined to comment on the report.

Brainstorm Cell's share price closed at $0.44 on Wall Street yesterday, giving a market cap of $52.6 million.

Published by Globes [online], Israel business news - www.globes-online.com - on August 4, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Biolight jumps on strong Zacks recommendation

Zacks cites the company for its technology, products, and meeting its targets.

VBL Therapeutics raises $40m in revived Nasdaq IPO

After the fiasco of the failed IPO in August, the drug development company scaled down the offering.

Assuta Hospital Gov't plans taxing private hospitals

The tax is one of the recommendations of the Economic Arrangments bill.

Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס